Skip to main contentSkip to navigation
Sirius Investors
Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

CLVLY
OTCHealthcare

Clinuvel Pharmaceuticals Limited (CLVLY) Investment Research Dashboard

About Clinuvel Pharmaceuticals Limited (CLVLY) stock analysis

Get live CLVLY stock price $7.01, comprehensive Clinuvel Pharmaceuticals Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time CLVLY stock data and investment insights.

7.01
0.86%Today
Market Cap
353.50M
Volume
1.30K
52W High
9.00
52W Low
5.98

Loading chart data...

Clinuvel Pharmaceuticals Limited (CLVLY) Overview

Clinuvel Pharmaceuticals Limited (CLVLY) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, CLVLY trades at $7.01 with a market capitalization of 353.50M . Over the past 52 weeks, CLVLY has traded between $5.98 and $9.00 , with the current price positioned at approximately 34% of this range . The stock curre...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 353.50M
  • Current price: $7.01
  • 52-week range: $5.98 - $9.00
  • P/E ratio: 16.20

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United Stat...

Company Information

CEO
Philippe Jacques Wolgen
Sector
Healthcare
Industry
Biotechnology
Employees
100

Contact Information

Address
535 Bourke Street
Country
AU

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 16.2)

Lower volatility stock (Beta: 0.61) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Clinuvel Pharmaceuticals Limited shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Clinuvel Pharmaceuticals Limited
  • Investors should consider how Clinuvel Pharmaceuticals Limited fits within their overall portfolio allocation

Market Cap

353.50M

P/E Ratio (TTM)

16.20

Beta

0.61

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.